Tulavi Therapeutics

Executive Summary

Tulavi Therapeutics is a private medical device company addressing the significant unmet need in peripheral nerve surgery, specifically neuroma prevention and improved nerve repair. Its lead innovation, the allay™ Hydrogel Cap, is a fully absorbable, hydrogel-based device designed to encapsulate the severed nerve end after amputation or injury. By physically sealing the nerve, the cap aims to reduce symptomatic neuroma formation—a painful complication that occurs in up to 30% of nerve transections—while also minimizing perineural adhesions and optimizing the local healing environment. The device is intended for use during initial nerve repair or revision procedures, and its absorbable nature eliminates the need for a second removal surgery. Tulavi is positioned to disrupt the standard of care, which currently lacks effective prophylactic options against neuroma. The company's technology was developed by leading peripheral nerve surgeons and material scientists, and it targets a large addressable market encompassing traumatic amputations, elective limb surgery, and oncologic resections. Early preclinical data have demonstrated reduced neuroma incidence and improved histologic nerve architecture. Tulavi is now advancing toward first-in-human studies, with regulatory submissions planned in the near term. If successful, the allay cap could become a standard adjunct in peripheral nerve surgery, improving patient outcomes and reducing chronic pain and opioid dependence. However, as a private startup, the company faces risks typical of early-stage medical device development, including regulatory hurdles, manufacturing scale-up, and competitive threats from alternative nerve capping technologies.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation60% success
• Q4 2026FDA IDE submission or 510(k) clearance pathway announcement50% success
• TBDSeries A or B funding round to support clinical development70% success